These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30031293)

  • 1. The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro.
    Loelius SG; Lannan KL; Blumberg N; Phipps RP; Spinelli SL
    Thromb Res; 2018 Sep; 169():96-104. PubMed ID: 30031293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets.
    Madzime M; Rossouw TM; Theron AJ; Anderson R; Steel HC
    Front Immunol; 2021; 12():634386. PubMed ID: 33777022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV protease inhibitor-induced cardiac dysfunction and fibrosis is mediated by platelet-derived TGF-β1 and can be suppressed by exogenous carbon monoxide.
    Laurence J; Elhadad S; Robison T; Terry H; Varshney R; Woolington S; Ghafoory S; Choi ME; Ahamed J
    PLoS One; 2017; 12(10):e0187185. PubMed ID: 29088262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
    Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
    Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV protease inhibitor ritonavir induces renal fibrosis and dysfunction: role of platelet-derived TGF-β1 and intervention via antioxidant pathways.
    Laurence J; Elhadad S; Gostynska S; Yu Z; Terry H; Varshney R; Fung KM; Choi ME; Ahamed J
    AIDS; 2020 Jun; 34(7):989-1000. PubMed ID: 32167970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
    Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of flow cytometry in the measurement of platelet activation and aggregation in human immunodeficiency virus infection.
    Nkambule BB; Davison G; Ipp H
    Platelets; 2015; 26(3):250-7. PubMed ID: 24831969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
    Murphy RL; Berzins B; Zala C; Fichtenbaum C; Dube MP; Guaraldi G; Torriani F; Belsey E; Mitchell C; Stein JH;
    AIDS; 2010 Mar; 24(6):885-90. PubMed ID: 19952712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent platelet activation and apoptosis in virologically suppressed HIV-infected individuals.
    Mesquita EC; Hottz ED; Amancio RT; Carneiro AB; Palhinha L; Coelho LE; Grinsztejn B; Zimmerman GA; Rondina MT; Weyrich AS; Bozza PT; Bozza FA
    Sci Rep; 2018 Oct; 8(1):14999. PubMed ID: 30301959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.
    O'Brien M; Montenont E; Hu L; Nardi MA; Valdes V; Merolla M; Gettenberg G; Cavanagh K; Aberg JA; Bhardwaj N; Berger JS
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):280-8. PubMed ID: 23406976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk.
    Taylor KA; Smyth E; Rauzi F; Cerrone M; Khawaja AA; Gazzard B; Nelson M; Boffito M; Emerson M
    Br J Pharmacol; 2019 Apr; 176(7):879-889. PubMed ID: 30681136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules.
    Khodadi E
    Cardiovasc Toxicol; 2020 Feb; 20(1):1-10. PubMed ID: 31784932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early ritonavir-induced maculopapular eruption.
    Bachmeyer C; Blum L; Cordier F; Launay E; Danne O; Aractingi S; Mougeot-Martin M
    Dermatology; 1997; 195(3):301-2. PubMed ID: 9407188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary protease inhibitors and cardiovascular risk.
    Lundgren J; Mocroft A; Ryom L
    Curr Opin Infect Dis; 2018 Feb; 31(1):8-13. PubMed ID: 29232276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
    Matoga MM; Hosseinipour MC; Aga E; Ribaudo HJ; Kumarasamy N; Bartlett J; Hughes MD;
    Antivir Ther; 2017; 22(3):205-213. PubMed ID: 27740537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.